Negative Points

• Quanterix Corp ( NASDAQ:QTRX ) reported a significant revenue shortfall in Q2, with total revenue of $32.9 million, approximately $3 million or 9% below guidance, leading to a substantial cut in full-year 2026 revenue guidance to $142-$148 million from $169-$174 million.

• The company's commercial execution initiatives have not yet delivered sustained revenue performance, prompting a reorganization of the sales force and a pivot to a solution-based selling model, which may cause near-term disruption.

• Quanterix Corp ( NASDAQ:QTRX ) experienced broad-based market softness, particularly in US academic and government spending, leading to a significant decline in Spatial revenue and a mid-teens percent drop in Pharma CRO revenue year-over-year.

• The company recorded a $26.9 million one-time non-cash goodwill impairment related to Akoya, reflecting macro factors and company performance, which negatively impacted GAAP operating expenses.

• Quanterix Corp ( NASDAQ:QTRX ) pushed its cash flow break-even target to 2027, with expected cash usage in the second half of 2026 to be in the double digits in Q3, indicating continued financial pressure.

• The Accelerator business declined significantly in Q2, mirroring trends toward smaller projects seen in Q1, and the company is creating a dedicated sales team to address this, but recovery is uncertain.

• Quanterix Corp ( NASDAQ:QTRX ) faces ongoing challenges in the Spatial market, with revenue declining across instruments and consumables due to weak funding, and the company does not expect a recovery in Academic/Gov spending in the near term.

Q & A Highlights

Q: Can you break down how you're thinking about instruments, consumables, and service in the back half of the year, and how Quanterix and Akoya will progress? A: Jason Faessler (CFO): We're not guiding to specific product lines, but we expect a couple of pickups in Simoa versus Spatial. We are not expecting any recovery in the Academic/Gov segment, so Spatial will lag compared to Simoa. We expect some pickup on the consumable side due to new assay releases, and there is a definite sequential improvement expected on the instruments side as well. Seasonally, H2 is higher, so we expect a pickup in the second half.

Q: What needs to get done specifically on the Akoya Spatial business to improve execution? A: Everett Cunningham (CEO): I'm optimistic about the Spatial business. Customer feedback on our new launches, like the PhenoCode molecular barcoding kit for the PCF platform and the new ADC lung cancer panel for the PhenoImager HT, has been positive. We are also segmenting our sales organization to have a dedicated, legacy Akoya team selling Spatial only. This prioritization will pay dividends in the second half and provide good sequential momentum.

Q: Can you update us on the FDA submission for LucentAD Complete and the key milestones for the diagnostics business over the next 12-18 months? A: Everett Cunningham (CEO): We are in productive dialogue with the FDA and believe we are on track for approval of our LucentAD Complete test towards the end of this year. We are also on track for the HD-X platform to be IVD ready in 2027. Geoff Albrecht (SVP, GM Diagnostics): We are scaling the team and working with partners on infrastructure and resources. The feedback from thought leaders at the AAIC conference was very positive, and the recent CMS pricing and payer dynamics are resonating well in the market.

Q: Why continue to invest in the diagnostics business when it won't pay near-term dividends and the research tools business is pressured? A: Everett Cunningham (CEO): Our strategy is an 'and' strategy. The research tools business is core, and we are taking steps to stabilize and grow it with new leadership. However, the diagnostics opportunity, specifically for Alzheimer's, is significant. We have a differentiated blood-based biomarker test, an instrument that will be IVD ready, and a dedicated team. The market is thirsty for earlier detection solutions, and we are well-positioned to grow this business sequentially.

Q: What happened with Spatial consumables and Simoa pull-through in the quarter? A: Everett Cunningham (CEO): The Spatial market is facing headwinds, especially in US Government and Academic accounts. Our job is to execute better in the second half with a singularly focused, segmented sales force. Jason Faessler (CFO): Simoa consumables were a bit weaker, likely linked to execution challenges. This is more of an execution issue, and the decisive steps being taken will impact the second half.

Q: How does the Anthem coverage influence other commercial plans to grant coverage for Alzheimer's tests? A: Geoff Albrecht (SVP, GM Diagnostics): The Anthem position puts us in a nice situation to approach other payers. Combined with our CMS pricing, it lines up the dominoes for what we are looking to do. We will apply a dedicated resource to work with local and national health plans, and we believe this first-mover experience with Anthem will help us line up additional opportunities.

Q: What are you assuming for Simoa versus Spatial versus Alzheimer's in the full-year guide, and why is there not risk for further guide cuts? A: Everett Cunningham (CEO): We have done a robust, bottoms-up look at our pipeline and funnel for each business. We feel confident in our second-half guide due to the momentum in diagnostics, the new leadership we are adding, and the renewed focus on sales execution. Jason Faessler (CFO): The decline for Spatial will likely continue into Q3 and Q4, similar to the first half, with more of a recovery on the Simoa side led by consumables and some sequential improvement in instruments.

Q: How are you thinking about the Spatial and Simoa businesses longer term, given the pivot to Alzheimer's diagnostics? A: Everett Cunningham (CEO): Our research tools business is absolutely core. We look to stabilize it, get it back to flat, and then start growing it. We have brought in Jim Gute to turn the research tools business around. We are also prudently investing in diagnostics with partnerships and leaders, and we expect that business to take off in 2027.

Q: Can you provide any benefits from the rapid CMS pathway and an update on the FDA side? A: Everett Cunningham (CEO): We are in regular, productive dialogue with the FDA, and we believe we are on track for approval of LucentAD Complete towards the end of this year. Geoff Albrecht (SVP, GM Diagnostics): We are super pleased with the CMS pricing for the multi-marker assay. It solidifies the value of our algorithm and is starting to take hold in the physician community, including primary care, memory centers, and neurologists.

Q: Is there a revenue number associated with hitting free cash flow break-even in 2027? A: Jason Faessler (CFO): We are not ready to talk about 2027 revenue at this time, but we are fully committed to cash break-even in 2027. We are also on track for growth ahead of the $10 million mentioned in Q1 for diagnostics, which is a great sign based on the partnerships from last year.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .